COLUMBUS, Ohio, Dec. 1, 2014 (GLOBE NEWSWIRE) -- N8 Medical, an emerging pharmaceutical company addressing life-threatening global health challenges through the development of high-value pharmaceutical and antimicrobial device solutions based on a patented, first-in-class small molecule technology, announces the recent publication of two separate reviews in peer-reviewed journals that highlight the potential for using its proprietary ceragenin platform to fight bacterial infections, including hospital acquired infections associated with medical devices and pulmonary infections associated with cystic fibrosis.
The first review, published in MedChemComm by the Royal Society of Medicine, and written by Drs. Ido Herzog and Micha Fridman, highlights N8 Medical's lead compound, CSA-13, indicating that it may "...offer a promising opportunity for the development of clinically useful and novel antibiotic agents that are likely to be safe for.... the prevention of biofilm formation on medical equipment and devices...."
The second review, "Ceragenins – a new weapon to fight multidrug resistant bacterial infections," published in Studia Medyczne, highlighted the variety of bacteria strains against which ceragenins may be useful. The review provides an overview of ceregenins' utility in fighting infections brought about by cystic fibrosis. The article concludes by discussing various uses for N8's lead compound, CSA-13. These include the potential prevention of microbial biofilm formation. It goes on to mention that CSA-13 may have antiparasitic, antiviral, and anticancer activity, may be used as a bactericide, and has the potential to be used in a controlled release mechanism (e.g., via contact lenses) and gene delivery.
"Review articles such as these continue to validate our clinical hypotheses, encouraging our march to the clinic," said Dr. Michael Triplett, CEO of N8 Medical. "Further, they demonstrate the multiple applications for ceragenins, which may ultimately provide N8 Medical with multiple opportunities for fighting bacterial infections, both in the near term as coatings for medical devices and in the longer term as potential therapeutics."
N8 Medical, Inc., is a privately held, emerging pharmaceutical company focused on the development of anti-infective therapies for the treatment of chronic cystic fibrosis infections and the development antimicrobial devices and coatings for the prevention of medical device-related hospital acquired infections. The company, based in Columbus, OH, is currently developing a first-in-class, novel anti-infective that may replicate how the human immune system kills pathogens.
CONTACT: Jules Abraham JQA Partners, LLC email@example.com 917-885-7378Source:N8 Medical, Inc.